Abelacimab Recruiting Phase 3 Trials for Atrial Fibrillation Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT05712200
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)